Divis Laboratories Q4 FY26 Earnings Preview Expectations Outlook

Wed Mar 18 2026

Divis Laboratories Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Divi’s Laboratories was listed on the National Stock Exchange (NSE) on 12-Mar-2003. Divi’s Laboratories share has its face value of 2 per share, and its NSE symbol is DIVISLAB. The company operates in the Pharma sector and primarily belongs to the API industry.

Table of Contents

Divi’s Laboratories Q4 Results 2026 Preview

Divi’s Laboratories Q4 FY26 revenue is expected to be around Strong Growth, representing a 18% YoY increase compared to the same quarter last year.
Profit After Tax, or PAT, is projected to rise 17% YoY.
EBITDA to rise 16%.
Divi’s Laboratories is expected to show Strong Growth in its revenue.

Click and Sign Up to Get Live Updates on Q4 Results

Divi’s Laboratories Share Performance

Over the past six months, Divi’s Laboratories share price has Positive by 16% to 6,117.50.
Moreover, over the past year, the stock has Positive by 28%
Despite this weak short-term performance, Divi’s Laboratories stock has delivered a financially sound 150% return over the past 5 years.
As of today, 18-03-2026, the Divi’s Laboratories share price is trading at 6,117.50 per share.

Key Factors to Watch for Divi’s Laboratories Q4 Results FY26

Revenue Growth & Segment Performance – Focus on topline growth in the API industry within the Pharma sector.
Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About Divi’s Laboratories

Divis Laboratories is a leading pharma company focusing on APIs and custom synthesis benefiting from export demand.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

Divi’s Laboratories is gear up to announce its Q4 FY26 results. Analysts expect 18% revenue growth, a 17% rise in PAT, and a 16% rise in EBITDA. Divi’s Laboratories focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Divi’s Laboratories Q4 results FY26.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.